Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company will engage in a fireside chat on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.
Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This event provides an opportunity for Pulmonx to showcase its innovations and discuss its position in the healthcare industry with potential investors and analysts.
Pulmonx (Nasdaq: LUNG), un leader nei trattamenti minimamente invasivi per malattie polmonari gravi, ha annunciato la sua partecipazione alla Wells Fargo Healthcare Conference 2024 a Boston. L'azienda parteciperà a un fireside chat giovedì 5 settembre 2024, alle 13:30 PT / 16:30 ET.
Investitori e parti interessate possono accedere a un webcast dal vivo e archiviato della presentazione attraverso la sezione 'Investitori' del sito web di Pulmonx all'indirizzo https://investors.pulmonx.com/. Questo evento offre a Pulmonx l'opportunità di mostrare le sue innovazioni e discutere la sua posizione nel settore sanitario con potenziali investitori e analisti.
Pulmonx (Nasdaq: LUNG), un líder en tratamientos mínimamente invasivos para enfermedades pulmonares severas, ha anunciado su participación en la Conferencia de Salud de Wells Fargo 2024 en Boston. La empresa participará en un fireside chat el jueves 5 de septiembre de 2024, a la 1:30 PM PT / 4:30 PM ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo y archivado de la presentación a través de la sección 'Inversores' del sito web de Pulmonx en https://investors.pulmonx.com/. Este evento brinda a Pulmonx la oportunidad de mostrar sus innovaciones y discutir su posición en la industria de la salud con posibles inversores y analistas.
Pulmonx (Nasdaq: LUNG)는 중증 폐질환을 위한 최소 침습 치료의 선두주자로서 보스턴에서 열리는 2024 웰스파고 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 2024년 9월 5일 목요일, 오후 1시 30분 PT / 오후 4시 30분 ET에 파이어사이드 챗에 참석할 예정입니다.
투자자 및 관심 있는 당사자들은 실시간 및 아카이브된 웹캐스트를 통해 Pulmonx 웹사이트의 '투자자' 섹션에서 프레젠테이션에 접근할 수 있습니다: https://investors.pulmonx.com/. 이 이벤트는 Pulmonx가 혁신을 선보이고 잠재적인 투자자 및 분석가와 함께 헬스케어 산업 내 입장을 논의할 기회를 제공합니다.
Pulmonx (Nasdaq: LUNG), un leader dans les traitements peu invasifs pour les maladies pulmonaires graves, a annoncé sa participation à la Conférence de Santé Wells Fargo 2024 à Boston. L'entreprise participera à un fireside chat le jeudi 5 septembre 2024, à 13h30 PT / 16h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct et archivé de la présentation via la section 'Investisseurs' du site web de Pulmonx à l'adresse https://investors.pulmonx.com/. Cet événement offre à Pulmonx l'occasion de présenter ses innovations et de discuter de sa position dans le secteur de la santé avec des investisseurs et des analystes potentiels.
Pulmonx (Nasdaq: LUNG), ein führendes Unternehmen für minimal-invasive Behandlungen von schweren Lungenerkrankungen, hat seine Teilnahme an der Wells Fargo Healthcare Conference 2024 in Boston angekündigt. Das Unternehmen wird am Donnerstag, den 5. September 2024, um 13:30 Uhr PT / 16:30 Uhr ET an einem Fireside Chat teilnehmen.
Investoren und interessierte Parteien können über den Bereich 'Investoren' auf der Pulmonx-Website unter https://investors.pulmonx.com/ auf einen live und archivierten Webcast der Präsentation zugreifen. Diese Veranstaltung bietet Pulmonx die Möglichkeit, seine Innovationen zu präsentieren und seine Position in der Gesundheitsbranche mit potenziellen Investoren und Analysten zu diskutieren.
- None.
- None.
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) presenting at the 2024 Wells Fargo Healthcare Conference?
Where can I watch the Pulmonx (LUNG) presentation at the Wells Fargo Healthcare Conference?
What type of presentation will Pulmonx (LUNG) give at the 2024 Wells Fargo Healthcare Conference?
Where is the 2024 Wells Fargo Healthcare Conference being held?
